Big Pharma and Suppressed Medical Treatments

Court documents proved Purdue Pharma knew OxyContin was highly addictive but marketed it as safe. The company pleaded guilty to federal criminal charges and paid over $8 billion in penalties.

A 2018 study in the BMJ found that 57% of FDA drug reviewers who left the agency between 2001 and 2017 went on to work for pharmaceutical companies, raising concerns about regulatory independence.

Gilead Sciences developed Harvoni/Sovaldi, which cures hepatitis C in 8-12 weeks, generating $44 billion in cumulative revenue — proving that cures can be more profitable than ongoing treatments.

Opioid manufacturers (Purdue, Endo, Johnson & Johnson), tobacco industry (confirmed cover-up), and various pharma settlements show a real pattern of industry misconduct.

Peer-reviewed research (Turner et al. NEJM 2008) documented significant publication bias in antidepressant trials — negative results underreported, inflating apparent efficacy.

US prescription-drug prices are several times higher than peer nations for equivalent drugs. This is partly a regulatory-capture issue (Medicare negotiation restrictions, patent evergreening) rather than conspiracy.

Purdue Pharma's OxyContin marketing was central to the opioid crisis; the Sackler family paid billions in settlements. Pattern of industry knowledge-of-harm + concealment is confirmed.

Claims of specific cures being suppressed (for cancer, Alzheimer's, etc.) generally lack primary evidence. Individual allegations have been investigated and typically found to be promotional hype for unproven alternative treatments.

Structural incentives in the pharmaceutical industry do favor expensive long-term treatments over one-time cures — but this is an economic problem, not a conspiracy. Cures that enter the pipeline (e.g. hepatitis C DAAs, Sovaldi) do get developed.

Many "suppressed cure" narratives are promoted by alternative-medicine proponents selling unverified treatments (laetrile, Gerson, etc.). FDA and FTC have taken action against fraud in this space.

Court documents proved Purdue Pharma knew OxyContin was highly addictive but marketed it as safe. The company pleaded guilty to federal criminal charges and paid over $8 billion in penalties.

A 2018 study in the BMJ found that 57% of FDA drug reviewers who left the agency between 2001 and 2017 went on to work for pharmaceutical companies, raising concerns about regulatory independence.

Opioid manufacturers (Purdue, Endo, Johnson & Johnson), tobacco industry (confirmed cover-up), and various pharma settlements show a real pattern of industry misconduct.

Peer-reviewed research (Turner et al. NEJM 2008) documented significant publication bias in antidepressant trials — negative results underreported, inflating apparent efficacy.

US prescription-drug prices are several times higher than peer nations for equivalent drugs. This is partly a regulatory-capture issue (Medicare negotiation restrictions, patent evergreening) rather than conspiracy.

Purdue Pharma's OxyContin marketing was central to the opioid crisis; the Sackler family paid billions in settlements. Pattern of industry knowledge-of-harm + concealment is confirmed.

Gilead Sciences developed Harvoni/Sovaldi, which cures hepatitis C in 8-12 weeks, generating $44 billion in cumulative revenue — proving that cures can be more profitable than ongoing treatments.

Claims of specific cures being suppressed (for cancer, Alzheimer's, etc.) generally lack primary evidence. Individual allegations have been investigated and typically found to be promotional hype for unproven alternative treatments.

Structural incentives in the pharmaceutical industry do favor expensive long-term treatments over one-time cures — but this is an economic problem, not a conspiracy. Cures that enter the pipeline (e.g. hepatitis C DAAs, Sovaldi) do get developed.

Many "suppressed cure" narratives are promoted by alternative-medicine proponents selling unverified treatments (laetrile, Gerson, etc.). FDA and FTC have taken action against fraud in this space.